Virus and TSE safety made simple

Published: 1-Aug-2011

27 - 28 September 2011
Seminar
Vienna, Austria

Viral safety is one of the major concerns in the development and production of biopharmaceuticals and biologics. Huge efforts are made to prevent viral contamination and a series of guidelines has been published dedicated exclusively to this subject. The nature of viruses poses particular challenges to the detection, inactivation and removal of viruses. All of these topics will be discussed at this course. It will also provide a sound introduction to TSE (Transmissable spongiform encephalopathy)

Organiser: Concept Heidelberg

Trending Articles

  1. Cleanroom Technology Conference UK 22–23 May 2024 | Conference and Exhibition | Birmingham, UK
  2. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany
  3. Lounges: Cleanroom Processes 17–19 May 2022 | Exhibition | Messe Karlsruher, Germany
  4. CPhI China 19-21 June 2024 | Conference | Shanghai, China
  5. Clinical Pharmacy Congress 10-11 May 2024 | Conference | London, UK

You may also like

Regulatory

The roadmap for supplier qualification

Wolfgang Schmitt of Concept Heidelberg explains the process required to minimise risks arising from outsourcing and ensure a good and steady relationship with suppliers
Regulatory

Deviations and CAPAs are hot topics in GMP inspections

GMP experts at the ECA Academy comment on a warning letter issued to Glenmark by the FDA
Design & Build

Editor’s comment: More than buzz words

It’s time to go beyond the gimmick as only companies aligned with the forefront of technology will capitalise on the advantages they bring
Regulatory

Medicinal cannabis: What it takes to be GMP-ready

The legalisation of cannabis for medicinal purposes pushes producers to supply chemists, physicians and patients with the newly approved drug in accordance with good manufacturing and distribution practices, as Dr Andrea Kühn-Hebecker explains
Regulatory

Procurement and GMP: A conflict in objectives?

A deeper understanding of the unique requirements and the underlying GMP guidelines is essential for purchasing in the pharmaceutical industry. Axel H. Schroeder of Concept Heidelberg, explains
Regulatory

Bioanalytical strategy: Authorities’ expectations to consider

Dr Markus Fido, analytical characterisation expert and VelaLabs co-founder, looks at the product lifecycle of biopharmaceuticals to describe the methods manufacturers should use to ensure required safety and quality under Directive 2001/83/EC
Regulatory

A lifecycle approach to the qualification of analytical procedures

Dr Christopher Burgess, ECA Analytical Quality Control Group, looks at the changing face of validation and explains the new APLM approach known as Analytical Procedure Lifecycle Management
Subscribe now